Debora Bonenfant

Vice-President, Head of Proteomics at Monte Rosa Therapeutics

Professional Overview
Debora Bonenfant is an experienced leader in the field of proteomics, currently serving as the Vice-President and Head of Proteomics at Monte Rosa Therapeutics. With a strong background in drug discovery research, she leverages her expertise in protein analysis and disease biology to drive innovative therapeutic solutions.

Experience Summary

Current Role
As the Vice-President and Head of Proteomics at Monte Rosa Therapeutics, Debora is responsible for overseeing the company's proteomics research initiatives. In this role, she leads a team of scientists in applying advanced mass spectrometry techniques to identify and characterize novel drug targets, with the goal of developing breakthrough therapies for complex diseases.

Career Progression
Debora has a distinguished career in the pharmaceutical and biotechnology industry, spanning nearly two decades. Prior to her current position, she held the role of Senior Director at Monte Rosa Therapeutics, where she was instrumental in establishing the company's proteomics capabilities and driving impactful research projects. Before joining Monte Rosa, Debora served as the Director of Proteomics at the company, and also held research positions at the Novartis Institutes for BioMedical Research (NIBR), where she made significant contributions to drug discovery efforts.

Academic Background
Debora holds a Ph.D. in Biochemistry from a leading Swiss university, with a focus on the application of mass spectrometry in protein analysis and structural biology. Her postdoctoral work at NIBR further honed her expertise in proteomics and its intersection with drug development.

Areas of Expertise

• Proteomics and mass spectrometry-based techniques

• Protein characterization and structural analysis

• Target identification and validation in drug discovery

• Translational research and biomarker discovery

• Team leadership and project management

Professional Impact
Debora has been a driving force in the advancement of proteomics-based drug discovery. Her work has led to the identification of several promising drug targets and the development of innovative analytical methods that have enhanced the efficiency of the drug discovery process. Debora is a respected member of the scientific community, having served on the board of the Swiss Proteomics Society and contributed to numerous industry conferences and publications.

Conclusion
With her deep expertise in proteomics, extensive industry experience, and proven track record of driving impactful research, Debora Bonenfant is well-positioned to lead Monte Rosa Therapeutics' efforts in harnessing the power of protein analysis to develop innovative, life-changing therapies.